Here's a look at some of the top Wall Street stories for medical device companies this week: Renal denervation isn't dead, despite Medtronic trial's failure; Baxter says HQ will stay in Illinois, stays coy on Boston plans; Private equity owners rebrand KCI, Systagenix, LifeCell as Acelity
Renal denervation isn't dead, despite Medtronic trial's failure
September 2, 2014 by Brad Perriello
Acelity, Apax Partners, Baxter International, Boston Scientific, Centaur Guernsey, Covidien, Kinetic Concepts Inc., Kona Medical, LifeCell Corp., Medtronic, ReCor Medical, St. Jude Medical, Systagenix Wound Management Inc.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1waxryH
Cap comentari:
Publica un comentari a l'entrada